Image beyond bone – into oncology, cardiovascular and pulmonary diseases, and much more, with the Quantum GX2 microCT imaging system. With the Quantum GX2, flexibility is key. Combining the ability to perform high speed, low dose scans, ideal for longitudinal studies, across multiple species (mice, rats, rabbits) with high resolution ex vivo scanning, the Quantum GX2 microCT imaging system offers the flexibility and performance you need to not just image, but further understand your disease models.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The Quantum GX2 microCT scanner is a true multispecies preclinical imaging system, offering the flexibility to enable longitudinal in vivo imaging as well as ex vivo sample scanning. With a 163mm imaging bore, an entire rabbit can be placed inside the scanner for in vivo scanning, while the 18mm FOV allows for high resolution scanning of ex vivo samples. Combined with PerkinElmer's 3-dimensional optical imaging systems, and automated bone analysis software (AccuCT™), the Quantum GX2 microCT imaging system provides maximal flexibility and function. Whether your research focus is oncology, cardiovascular disease, orthopedics or pulmonary disease, the Quantum GX2 is versatile enough to deliver the results you need.
Combine the Quantum GX2 microCT imaging with PerkinElmer's other in vivo imaging modalities (optical and PET) to gain greater insight into disease progression and treatment response non-invasively.
|Imaging Modality||microCT Imaging|
|Product Brand Name||Quantum|
X-ray CT imaging is commonly used for skeletal imaging as bones are densely mineralized tissues with excellent x-ray attenuation properties. In contrast, soft, less dense tissues often prove to be challenging to image due to their lack of sufficient tissue density. Soft tissues such as muscle, blood vessels and internal organs share similar x-ray attenuation characteristics and are not distinguishable under typical CT settings. In order to introduce density that would improve soft tissue contrast, several contrast agents have been developed for use in clinical and preclinical settings. This application note outlines the use of iodine and nanoparticle-based contrast agents for imaging soft tissues and vasculature in various organs using the Quantum GX to gain further insights into disease and therapeutic response.
Osteoarthritis (OA) is the most common form of arthritis and affects a considerable portion of the elderly population. In the U.S., it is estimated that more than 630 million people worldwide have this chronic condition, generally in the knees. OA occurs when the cartilage that cushions the ends of bones within the joints gradually deteriorates, causing synovitis and joint deformation.
The goal of OA research is to identify new therapeutic strategies that could prevent, reduce, halt progression, or repair the existing damage to the joint. Non-invasive in vivo imaging such as microCT is the standard modality for bone research due to its ability to obtain high-resolution images at an x-ray dose low enough as not to harm the animal. This makes microCT ideal for monitoring disease progression and response to treatments in the same animal over time. However, microCT data visualization and analysis can be cumbersome and time consuming. In this application note, we compared standard microCT software and advanced bone software to investigate bone erosion in an OA rat model.
Pulmonary Arterial Hypertension (PAH) is a life-threatening disease that affects the arteries in the lungs and the right side of the heart. Small animal models are often used in experimental PAH research due to their similarities to human cardiovascular physiology. MRI and microPET are established tools in evaluating RV function and physiology but both can present certain challenges including complex acquisition techniques, high imaging costs and accessibility. Conversely, microCT offers superior resolution, rapid data acquisition, and ease-of-use. Read this editorial and article published in the December issue of Circulation on how researchers report on the first quantitative assessment of RV and left ventricular systolic and diastolic volumes and function in an experimental model of PAH using the Quantum GX2 microCT imaging system.
It’s simple: More information means more understanding,For today’s researchers in oncology, infectious diseases, inflammation, neuroscience, stem cells,and other disciplines, there’s an increasing need for in vivo imaging that enables you to visualize,multiple events simultaneously and to extract the maximum amount of information from each,subject – leading to greater biological understanding.,Multimodal imaging enables a better understanding of disease biology. By utilizing in vivo,optimized bioluminescent and fluorescent agents and radioactive probes, researchers can,measure depth, volume, concentration, and metabolic activity, providing a wealth of information,for untangling the mysteries of disease.,Coregistration allows researchers to overlay images from multiple imaging modalities, providing,more comprehensive insight into the molecular and anatomical features of a model subject.,For example, optical imaging data can be used to identify and quantify tumor burden at,the molecular level and, when integrated with microCT, provides a quantitative 3D view of,anatomical and functional readouts.,At PerkinElmer, we’ve developed industry leading imaging technology for preclinical research.,Our technology integrates 3D optical and PET modalities with microCT to provide a better,understanding of disease. And that means better monitoring of disease progression, earlier,detection of treatment efficacy, and deeper understanding of metabolic changes that take place,throughout disease development.
Product Note - Quantum GX microCT imaging system
Multimodal co-registration optical, microCT and PET imaging
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.